
Roche, Genentech tap regenerative cell therapy player for drug collaboration in eye disease
In a lucrative market for ocular degeneration, Roche has long sat on a gold mine with its drug Lucentis — but the times are changing, and the drugmaker is looking to add to its ocular portfolio. Now, Roche will bet on a regenerative approach to eye disease with a small biotech with some very early but promising data.
Genentech will pay $50 million upfront and a potential $620 million in downstream milestones for licensing rights to Lineage Cell Therapeutics’ OpRegen program, a cell therapy that aims to regenerate healthy versions of retinal pigment epithelial cells in patients’ eyes, the companies said Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.